Journal
CLINICAL CANCER RESEARCH
Volume 28, Issue 18, Pages 3929-3939Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-21-3304
Keywords
-
Categories
Funding
- Research Council VUB
- Stichting tegen Kanker
- VLAIO
- Oncology Research Center
- Belgian Foundation against Cancer [FAF-C/2018/1222 (2018-128), FAF-F/2018/1223 (2018-089)]
- Flanders Innovation and Entrepreneurship (VLAIO) [HBC.2019.2522, HBC.2019.2564]
- Research Council of the Vrije Universiteit Brussel
- Scientific Fund Willy Gepts
Ask authors/readers for more resources
This review discusses the recent advances and clinical applications of RNA-based immuno-oncology, including its manufacturing, safety, and potential challenges.
? ABSTRACT Recent advances in the manufacturing, modification, purification, and cellular delivery of ribonucleic acid (RNA) have enabled the development of RNA-based therapeutics for a broad array of applications. The approval of two SARS-CoV-2-targeting mRNA-based vaccines has highlighted the advances of this technology. Offering rapid and straightforward manufacturing, clinical safety, and versatility, this paves the way for RNA therapeutics to expand into cancer immunotherapy. Together with ongoing trials on RNA cancer vaccination and cellular therapy, RNA therapeutics could be introduced into clinical practice, possibly stewarding future personalized approaches. In the present review, we discuss recent advances in RNA-based immuno-oncology together with an update on ongoing clinical applications and their current challenges.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
